| | | Spinal disorders | value | Postherpetic neuropathy | value | Diabetic neuropathy | value | | Outpatient | Inpatient | Outpatient | Inpatient | Outpatient | Inpatient |
| | 21144 | 2358 | | 2435 | 360 | | 1244 | 234 | | | Sex (male), (%) | 10219 (48.3) | 1211 (51.4) | 0.006 | 1142 (46.9) | 168 (46.7) | 0.935 | 745 (59.9) | 146 (62.4) | 0.473 | | Age, mean (SD) | 67.3 (13.9) | 70.0 (13.1) | <0.001 | 69.1 (13.2) | 70.8 (13.0) | 0.030 | 67.7 (11.7) | 69.1 (11.6) | 0.084 | | Initial daily dose (mg), mean (SD) | 89.5 (54.1) | 101.4 (56.8) | <0.001 | 108.0 (58.7) | 104.8 (52.6) | 0.321 | 96.9 (54.2) | 99.1 (57.8) | 0.570 | | Maximum daily dose (mg), mean (SD) | 115.2 (76.4) | 140.0 (92.9) | <0.001 | 146.5 (96.9) | 164.5 (106.2) | 0.002 | 129.9 (85.1) | 139.1 (92.6) | 0.135 | | Prescription period (day) | | | | | | | | | | | Mean (SD) | 123.6 (128.2) | 95.7 (116.1) | <0.001 | 95.2 (116.5) | 94.0 (112.8) | 0.857 | 160.3 (143.6) | 103.2 (124.1) | <.0.001 | | Median (25, 75 percentile) | 62 (28, 196) | 43 (15, 122) | <0.001 | 42 (14, 119) | 43.5 (20, 111.5) | 0.600 | 91 (30, 365) | 43 (17, 129) | <0.001 | | Prescription period over 90 days, (%) | 8726 (41.3) | 724 (30.7) | <0.001 | 747 (30.7) | 105 (29.2) | 0.562 | 634 (51.0) | 74 (31.6) | <0.001 | | Coprescribed oral drugs, mean (SD) | 4.0 (3.7) | 5.5 (4.2) | <0.001 | 4.3 (3.7) | 5.4 (4.0) | <0.001 | 7.0 (4.4) | 7.4 (4.6) | 0.232 | | 1-2-line drugs, (%) | 2798 (13.2) | 272 (11.5) | 0.021 | 350 (14.4) | 49 (13.6) | 0.670 | 171 (13.7) | 31 (13.2) | 0.839 | | Opioids, (%) | 881 (4.2) | 322 (13.7) | <0.001 | 95 (3.9) | 33 (9.2) | <0.001 | 33 (2.7) | 21 (9.0) | <0.001 | | NSAIDs, (%) | 8813 (41.7) | 1119 (47.5) | <0.001 | 959 (39.4) | 164 (45.6) | 0.026 | 264 (21.2) | 63 (26.9) | 0.054 |
| | | Cancer-related pain | value | Trigeminal neuralgia | value | Entrapment neuropathy of the upper limb | value | | Outpatient | Inpatient | Outpatient | Inpatient | Outpatient | Inpatient |
| | 2172 | 1761 | | 713 | 67 | | 1251 | 78 | | | Sex (male), (%) | 1167 (53.7) | 1089 (61.8) | <0.001 | 320 (44.9) | 31 (46.3) | 0.828 | 499 (39.9) | 37 (47.4) | 0.188 | | Age, mean (SD) | 64.3 (12.2) | 65.0 (12.6) | 0.060 | 65.9 (13.7) | 68.9 (12.8) | 0.079 | 65.4 (14.2) | 68.7 (12.7) | 0.044 | | Initial daily dose (mg), mean (SD) | 108.3 (54.2) | 107.1 (58.8) | 0.515 | 109.9 (60.2) | 117.4 (69.8) | 0.337 | 84.4 (52.7) | 93.1 (60.7) | 0.161 | | Maximum daily dose (mg), mean (SD) | 150.0 (96.4) | 165.1 (116.7) | <0.001 | 148.7 (97.3) | 165.5 (93.2) | 0.176 | 107.8 (74.3) | 142.8 (124.8) | <0.001 | | Prescription period (day) | | | | | | | | | | | Mean (SD) | 118.3 (123.2) | 72.3 (92.4) | <0.001 | 124.0 (135.2) | 76.6 (100.3) | 0.006 | 125.6 (128.4) | 126.9 (137.0) | 0.935 | | Median (25, 75 percentile) | 63 (28, 177) | 36 (14, 84) | <0.001 | 51 (14, 220) | 39 (16, 88) | 0.371 | 63 (28, 204) | 54 (21, 228) | 0.631 | | Prescription period over 90 days, (%) | 888 (40.9) | 418 (23.7) | <0.001 | 287 (40.3) | 15 (22.4) | 0.005 | 520 | (41.6) | 31 (39.7) | | Coprescribed oral drugs, mean (SD) | 5.1 (3.4) | 5.7 (3.5) | <0.001 | 4.1 (4.0) | 6.4 (4.3) | <0.001 | 3.8 (3.9) | 5.8 (4.2) | <0.001 | | 1-2-line drugs, (%) | 93 (4.3) | 84 (4.8) | 0.463 | 82 (11.5) | 7 (10.4) | 0.796 | 201 (16.1) | 11 (14.1) | 0.646 | | Opioids, (%) | 1001 (46.1) | 1127 (64.0) | <0.001 | 25 (3.5) | 8 (11.9) | 0.001 | 28 (2.2) | 7 (9.0) | <0.001 | | NSAIDs, (%) | 1111 (51.2) | 1035 (58.8) | <0.001 | 161 (22.6) | 33 (49.3) | <0.001 | 363 (29.0) | 34 (43.6) | 0.007 |
|
|
